Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor

  • Ila Mishra
  • , Wei Rose Xie
  • , Juan C. Bournat
  • , Yang He
  • , Chunmei Wang
  • , Elizabeth Sabath Silva
  • , Hailan Liu
  • , Zhiqiang Ku
  • , Yinghua Chen
  • , Bernadette O. Erokwu
  • , Peilin Jia
  • , Zhongming Zhao
  • , Zhiqiang An
  • , Chris A. Flask
  • , Yanlin He
  • , Yong Xu
  • , Atul R. Chopra

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Asprosin is a fasting-induced glucogenic and centrally acting orexigenic hormone. The olfactory receptor Olfr734 is known to be the hepatic receptor for asprosin that mediates its effects on glucose production, but the receptor for asprosin's orexigenic function has been unclear. Here, we have identified protein tyrosine phosphatase receptor δ (Ptprd) as the orexigenic receptor for asprosin. Asprosin functions as a high-affinity Ptprd ligand in hypothalamic AgRP neurons, regulating the activity of this circuit in a cell-autonomous manner. Genetic ablation of Ptprd results in a strong loss of appetite, leanness, and an inability to respond to the orexigenic effects of asprosin. Ablation of Ptprd specifically in AgRP neurons causes resistance to diet-induced obesity. Introduction of the soluble Ptprd ligand-binding domain in the circulation of mice suppresses appetite and blood glucose levels by sequestering plasma asprosin. Identification of Ptprd as the orexigenic asprosin receptor creates a new avenue for the development of anti-obesity therapeutics.

Original languageEnglish
Pages (from-to)549-563.e8
JournalCell Metabolism
Volume34
Issue number4
DOIs
StatePublished - Apr 5 2022

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Inc.

Funding

We thank Andrew Pieper, Seth Field, and members of the Chopra lab for helpful suggestions and critical reading of the manuscript. This work was supported by the NIDDK (DK102529 and DK118290). Formal analysis, I.M.; investigation, I.M. W.R.X. J.C.B. Y.H. C.W. E.S.S. H.L. Z.K. Y.C. and B.O.E.; methodology, I.M. and W.R.X.; writing—original draft, I.M.; analysis, P.J.; supervision, Z.Z. Z.A. C.A.F. Y.X. and A.R.C.; resources, Z.A. C.A.F. Y.X. and A.R.C.; investigation, Y.H.; conceptualization, A.R.C.; funding acquisition, A.R.C.; writing—review & editing, A.R.C. Atul Chopra has been awarded asprosin-related patents and is a co-founder, director, and officer of Vizigen, Inc. and Aceragen, Inc. and holds equity in both companies. The other authors declare no competing interests. We thank Andrew Pieper, Seth Field, and members of the Chopra lab for helpful suggestions and critical reading of the manuscript. This work was supported by the NIDDK ( DK102529 and DK118290 ).

FundersFunder number
A.R.C. A.R.C.
Andrew Pieper
Seth Field
National Institute of Diabetes and Digestive and Kidney DiseasesR01DK125403, DK118290, DK102529
National Institute of Diabetes and Digestive and Kidney Diseases

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • AgRP
    • Ptprd
    • appetite
    • asprosin
    • hypothalamus
    • metabolism
    • obesity
    • receptor

    ASJC Scopus subject areas

    • Physiology
    • Molecular Biology
    • Cell Biology

    Fingerprint

    Dive into the research topics of 'Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor'. Together they form a unique fingerprint.

    Cite this